PRODUCT / UROLITHIN A
Urolithin A Powder.
Defined for product development.
Urolithin A ingredient information for sample screening, documentation review and qualified commercial procurement.
Bulk ingredient for technical evaluation
Confirm current lot specification and method
What to confirm,
and on what terms.
The fields below show what to confirm before ordering. Final limits, methods, pack sizes and terms belong in the current specification, lot documents and quotation. Tell us your destination market, intended format and importer role so the request can be reviewed.
A · Quality & specification
B · Packaging, storage & shipping
C · Commercial
Request the current COA, TDS and SDS with your sample enquiry. Confirm which documents apply to the selected lot and agreed specification. Review our quality and documentation process, then send your requirements through the procurement brief.
98% vs 99% HPLC: what to compare
The assay target is only one line of a purchase specification. Confirm the analytical method, related-substance profile, current lot and intended format before choosing a grade. Ask which assay grades are currently offered and request the corresponding lot specification and quotation.
| Review point | 98% HPLC route | 99% HPLC route |
|---|---|---|
| Assay target | Request the current lot result and method for a 98% target. | Request the current lot result and method for a 99% target. |
| Related substances | Review the named panel and limits on the lot COA. | Review the same panel; a higher assay alone does not define each impurity limit. |
| Price range | Quote after quantity, packaging, market and document needs are known. | Quote against current lot availability and the same commercial brief. |
| Suitable formats | Screen the intended capsule, tablet, powder, gummy or liquid system in the buyer's process. | Use the same formulation tests; a higher assay does not by itself establish better format fit. |
No price band or impurity limit is stated without a current quotation and specification. See how we frame quality review and the evidence boundary.
Built to be
formulated with.
Urolithin A is a crystalline powder with low water solubility. The practical starting point is to choose a delivery system, then check wetting, dispersion, blend uniformity, process exposure and finished-product stability in your own base.
Use the examples as bench-development directions for an internal technical brief. They are not consumer dosage recommendations, and final composition, process limits and release criteria must be set against the current TDS and your destination-market requirements.
For market and format context, review our application pathways before fixing the formulation brief.
Send a formulation briefHard capsule — direct blend
Urolithin A 30% w/w of fill · microcrystalline cellulose q.s. · colloidal silicon dioxide 0.5% · magnesium stearate 0.75%Low-shear blend for 10–15 minutes as a bench starting point. Size the capsule from the tapped density of the finished blend, not the raw powder alone.
Tablet — granulated
Urolithin A 40% w/w · PVP K30 3% as binder · MCC and lactose q.s. · croscarmellose sodium 3% · magnesium stearate 0.75%Evaluate granulation moisture, compression behaviour, disintegration and content uniformity across the full compression run.
Stick pack and RTD powder
Urolithin A 20% w/w · agglomerated base q.s. · acidity and flavour to profile · colloidal silicon dioxide 0.5% as flow aidScreen particle-size distribution, wetting and settling before fixing fill weight or claiming a uniform ready-to-drink dispersion.
Gummy — pectin, low-temperature deposit
Urolithin A 15% w/w · pectin–sucrose base q.s. · citric acid to pH 3.2–3.6 · colour and flavour to profileRun a short thermal-hold and post-deposit assay check on the selected base before scaling the process.
Oil suspension and softgel
Urolithin A 12% w/w · MCT or high-oleic sunflower oil q.s. · lecithin 1% as wetting agent · fumed silica 1–2% as anti-settling aidWet the particle before thickening the oil, then check sedimentation, redispersibility and fill homogeneity over the intended shelf-life study.
Low-moisture HPMC capsule
Urolithin A 25–35% w/w of fill · MCC and mannitol q.s. · colloidal silicon dioxide 0.3–0.5% · sodium stearyl fumarate 0.5–0.75%Useful when the brief favours a plant-based capsule shell. Compare fill-weight variation, water activity, shell compatibility and disintegration against the selected HPMC shell.
Chewable tablet — mannitol base
Urolithin A 10–20% w/w · mannitol–isomalt base q.s. · crospovidone 2–4% · flavour and acid system to profile · magnesium stearate 0.5–0.75%Screen mouthfeel, blend uniformity, tablet hardness, friability and assay after compression; the flavour system should be evaluated with the active material, not alone.
Effervescent granule — moisture barrier
Urolithin A 5–10% w/w · anhydrous citric acid and sodium bicarbonate q.s. · mannitol q.s. · flow aid to process requirementRun compatibility and moisture-uptake trials before scale-up. Confirm dispersion time, pH, assay recovery and pack performance in the final high-barrier sachet or tube.
Protein matrix powder
Urolithin A 5–10% w/w · whey or pea protein q.s. · lecithin 0.5–1% · inulin or maltodextrin q.s. · colloidal silicon dioxide 0.3–0.5%Evaluate segregation during blending, wetting in the protein matrix, sedimentation after reconstitution and flavour carry-through at the intended serving volume.
Emulsified ready-to-drink system
Urolithin A pre-dispersion at target assay · MCT or phospholipid carrier phase q.s. · emulsifier system to screen · buffer and flavour to profileTreat this as a process-led route: screen pre-wetting, homogenisation energy, droplet-size distribution, pH drift, creaming and assay recovery through the intended shelf-life study.
All loadings are illustrative w/w starting points for formulation development — not intake or dosage guidance. Confirm each number against the current specification, excipient grade, process capability, finished-product testing and applicable local requirements.
We are a professional Urolithin A manufacturing factory.
Urolithin A is manufactured in our own facility on a single in-house route: microbial fermentation under controlled culture conditions. Tell us your intended format, destination market, target specification and expected quantity so we can route the right response.
Request a 20 g evaluation sample
Use the brief below to request a 20 g sample for internal technical evaluation. State the grade under review, destination market, intended format and tests you plan to run. Availability, lot documents, shipping arrangements and any charges are confirmed in the reply; submitting this form does not reserve a sample.
This page supports qualified B2B ingredient evaluation and procurement. Confirm the applicable specification, documentation, regulatory status and finished-product requirements for each destination market before purchase or use.
Short answers for
technical review.
These answers support formulation, procurement and QA review. They do not replace the current specification, lot documents or destination-market assessment.
What documents can I request for Urolithin A?
Qualified buyers can request the applicable specification, lot COA, TDS, SDS, analytical method summary and packaging information. The final document set depends on the confirmed grade, destination market and project stage.
Can I request a Urolithin A sample?
Yes. Sample size, shipping conditions and the sample-lot document set should be confirmed in the enquiry. The sample should be linked to a traceable lot and its applicable COA.
Can Urolithin A be evaluated for beverage formulations?
It can be evaluated for beverage development, but the material has low aqueous solubility. Wetting, dispersion, suspension stability, particle profile, process exposure and assay recovery should be checked in the target base before a commercial decision.
What should a Urolithin A RFQ include?
Include the destination market, product format, target assay, estimated quantity, packaging preference, documentation needs, project stage and expected timing. These details help align the quotation with the right specification and delivery route.
What does CAS 1143-70-0 identify?
CAS 1143-70-0 is the public reference identifier for Urolithin A. Identity, assay, related substances and release criteria must still be confirmed against the current batch specification and analytical record.
Request the current COA, TDS and SDS with your sample or quotation brief so the document set can be matched to the confirmed grade and market.